Kohei Shitara, Medical oncologist at National Cancer Center Hospital East, Japan, shared a post on X/Twitter:
“Happy to report ctDNA analysis of PARADIGM at Nature Medicine. Negative hyper selection enriched the benefit of panitumumab for colorectal cancer regardless of sidedness. Does tumor location serve as a surrogate for molecular type?”
Source: Kohei Shitara/X